TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9987703

Group type: EXPERIMENTAL
Intervention: Erythromycin 333 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study: 7539109

Group type: EXPERIMENTAL
Intervention: lenograstim (5 micrograms per kilogram of body weight per day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 173
Study: 2272188

Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin (75 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sustained-release diclofenac sodium (100 mg)
Number of subjects: 84
Study: 7394133

Group type: EXPERIMENTAL
Intervention: Start 3
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Start 7
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Finish 3
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Finish 7
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All groups (TE and RT tasks)
Number of subjects: 34
Study: 30612775

Group type: EXPERIMENTAL
Intervention: Arthroscopic labral reconstruction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Labral repair (control)
Number of subjects: 34
Study: 27492799

Group type: COMPARATOR
Intervention: Control implants (Osseotite) with dual acid‐etched (DAE) surface in the apical portion and a machined coronal part.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Test implants (Full Osseotite, FOSS) which were completely DAE.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both control and test implants.
Number of subjects: 10
Study: 26647864

Group type: EXPERIMENTAL
Intervention: ESM self-monitoring with weekly feedback sessions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ESM self-monitoring without feedback
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 102
Study: 23262301

Group type: EXPERIMENTAL
Intervention: Baclofen 10mg t.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active placebo (cyproheptadine 2mg t.i.d.)
Number of subjects: 14
Study: 19713300

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 44
Study: 19815466

Group type: EXPERIMENTAL
Intervention: Creon 24,000 units
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17959387

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Simvastatin (40 mg/day)
Number of subjects: 10
Study: 14551167

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 28

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nCPAP withdrawal
Number of subjects: 28
Study: 11878058

Group type: EXPERIMENTAL
Intervention: lipantil 200 M
Number of subjects: 40

Group type: COMPARATOR
Intervention: healthy men (control group)
Number of subjects: 40
Study: 10052105

Group type: EXPERIMENTAL
Intervention: Sport games (indoor soccer and basketball)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional cardiovascular fitness activities (step aerobics and running)
Number of subjects: 0
Study: 7972831

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iohexol)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ionic contrast medium (ioxaglate)
Number of subjects: 14
Study: 2751973

Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (1.0, 2.5, or 10 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (1.0 microgram daily or 0.5 microgram twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (10 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops
Number of subjects: 0
Study: 596497

Group type: EXPERIMENTAL
Intervention: Health education program (tutorial, home safety-proofing assignments, and follow-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study: 30531383

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stretching (active control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tango
Number of subjects: 96
Study: 28922709

Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 80
Study: 27277189

Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg single dose)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sonidegib with esomeprazole (40 mg pre-treatment for 5 days, combination on day 6)
Number of subjects: 42
Study: 22484721

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 20220284

Group type: EXPERIMENTAL
Intervention: Educational program on pregnancy and delivery (3 weeks, once a week for two hours)
Number of subjects: 0
Study: 18711187

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for early relapse (ER)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for late relapse (LR)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for MRD-negative patients
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for MRD-positive patients
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks)
Number of subjects: 124
Study: 16338726

Group type: EXPERIMENTAL
Intervention: gym ball crunch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: legs raised crunch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 kg weight crunch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: standard crunch (sit-up) with bent knees
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: roller crunch
Number of subjects: 15

Group type: COMPARATOR
Intervention: post-fatigue (LRA and URA)
Number of subjects: 15
Study: 14608279

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 0
Study: 10472596

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg/24 h for 3 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cefuroxime (ACF) 500 mg/12 h for 10 days
Number of subjects: 101
Study: 8671508

Group type: EXPERIMENTAL
Intervention: IVF and embryo transfer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historical comparison group (C)
Number of subjects: 12
Study: 2013951

Group type: EXPERIMENTAL
Intervention: Continuous support of a doula
Number of subjects: 412

Group type: COMPARATOR
Intervention: Monitoring by an inconspicuous observer
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (after delivery)
Number of subjects: 412
Study: 6138592

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 232

Group type: COMPARATOR
Intervention: Azathioprine and steroids (Control)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study: 31912560

Group type: EXPERIMENTAL
Intervention: NTS curriculum (n = 21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control curriculum (n = 18)
Number of subjects: 39
Study: 30667279

Group type: EXPERIMENTAL
Intervention: rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 27395
Study: 28862934

Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 26291648

Group type: EXPERIMENTAL
Intervention: E-cigarette use (30 puffs 30 seconds apart)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-nicotine-containing e-cigarette
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicotine-containing e-cigarette
Number of subjects: 30
Study: 24392086

Group type: EXPERIMENTAL
Intervention: Preventive medication for osteoporosis (specific medication not detailed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Engagement with supportive professionals
Number of subjects: 30
Study: 21725374

Group type: EXPERIMENTAL
Intervention: High-dose therapy with auto-SCT (Arm B)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional chemotherapy (Arm A)
Number of subjects: 86
Study: 19652123

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline (target doses of 15 to 20 mg of olanzapine per day plus masked sertraline at 150 to 200 mg per day)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus placebo (target doses of 15 to 20 mg of olanzapine per day plus masked placebo)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus sertraline and Olanzapine plus placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 259
Study: 17449082

Group type: EXPERIMENTAL
Intervention: High-density EEG investigation of cortical processing of a rotating visual pattern
Number of subjects: 4
Study: 16785332

Group type: EXPERIMENTAL
Intervention: Water (H2O)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Salt water (NaCl-H2O)
Number of subjects: 9
Study: 15577460

Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 92
Study: 11246648

Group type: EXPERIMENTAL
Intervention: Support program for caregivers of dementia patients
Number of subjects: 49
Study: 8971314

Group type: EXPERIMENTAL
Intervention: Paracetamol elixir 40 mg/kg preoperatively (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol suppositories 40 mg/kg after induction of anaesthesia (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paracetamol elixir (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol suppositories (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children with plasma paracetamol concentrations above 0.07 mmol/l
Number of subjects: 100
Study: 1281078

Group type: EXPERIMENTAL
Intervention: Cheek electrodes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sphenoidal electrodes
Number of subjects: 22
Study: 3883968

Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 96
Study: 30958329

Group type: EXPERIMENTAL
Intervention: Neck stabilization exercise and breathing retraining exercise (15 minutes each) in addition to rehabilitation exercise treatment.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Breathing retraining exercise (30 minutes) in addition to rehabilitation exercise treatment.
Number of subjects: 30
Study: 27777235

Group type: EXPERIMENTAL
Intervention: Selenium (as selenomethionine)
Number of subjects: 6546

Group type: EXPERIMENTAL
Intervention: Vitamin E (as α‐tocopherol)
Number of subjects: 6546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6546
Study: 25873045

Group type: EXPERIMENTAL
Intervention: Gefitinib plus Fuzheng Kang'ai decoction (FZKA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 70
Study: 24063435

Group type: EXPERIMENTAL
Intervention: Structured Community Health Worker (CHW)‐provided home visits
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care received through the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) office visits
Number of subjects: 140
Study: 21048039

Group type: EXPERIMENTAL
Intervention: Cetuximab plus platinum/5‐fluorouracil (5‐FU)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Platinum/5‐fluorouracil (5‐FU) alone
Number of subjects: 442
Study: 19766902

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5mg daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18044061

Group type: EXPERIMENTAL
Intervention: Anticholinergic bronchodilator
Number of subjects: 0

Group type: COMPARATOR
Intervention: β-agonist bronchodilator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of β-agonists and anticholinergics
Number of subjects: 0

Group type: COMPARATOR
Intervention: β-agonists added to anticholinergic or inhaled corticosteroid use
Number of subjects: 0
Study: 15110023

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11136927

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with preserved autoregulation
Number of subjects: 18
Study: 9389815

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7950288

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (6 x 50 mg Fe2+ aspartate/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parenteral iron therapy (0.75 mg/kg BW complex‐bound Fe3+ once a week by infusion)
Number of subjects: 60
Study: 2891224

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg once at night
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg bid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg bid
Number of subjects: 48

Group type: COMPARATOR
Intervention: ranitidine 150 mg bid
Number of subjects: 48
Study: 31420120

Group type: EXPERIMENTAL
Intervention: Oral melatonin for 21 consecutive days
Number of subjects: 30
Study: 31013189

Group type: EXPERIMENTAL
Intervention: CVC-related infection (CRI) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-CRI group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CVC duration in CRI group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total hospital length of stay (LOS) in CRI group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Annual CRI rates
Number of subjects: 100
Study: 28610880

Group type: EXPERIMENTAL
Intervention: Laparoscope-Assisted TAP (LTAP) block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasound-Guided TAP (UTAP) block
Number of subjects: 80
Study: 25205008

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia plus treatment as usual (TAU)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 37
Study: 22476926

Group type: EXPERIMENTAL
Intervention: Protein ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 10
Study: 21272713

Group type: EXPERIMENTAL
Intervention: Inspiratory muscular training (IMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no threshold resistance valve)
Number of subjects: 21
Study: 19861886

Group type: EXPERIMENTAL
Intervention: Ligation of the distal vein in AVF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-ligated group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16505644

Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide (0.5 g.kg‐1.day‐1; Ala‐Gln group, n=58)
Number of subjects: 114

Group type: COMPARATOR
Intervention: L-alanine+L-proline (control group, n=56)
Number of subjects: 114
Study: 15008374

Group type: EXPERIMENTAL
Intervention: Three-dimensional geometrical characterization of aneurysm sac using indices such as maximum diameter, neck diameter, height, aspect ratio, bottleneck factor, bulge location, volume, surface area, Gaussian and mean curvatures, isoperimetric ratio, and convexity ratio.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Size-matched hypothetical control aneurysms.
Number of subjects: 9
Study: 14768792

Group type: EXPERIMENTAL
Intervention: Mega-dose methylprednisolone (MDMP) 30 mg/kg/d for 3 days and 20 mg/kg/d for 4 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/d for 2 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: MDMP
Number of subjects: 42

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 42
Study: 10809263

Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (15 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (5 cm H2O) with inverse I:E ratio (2:1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (5 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of all settings (A, B, C)
Number of subjects: 22
Study: 9123923

Group type: EXPERIMENTAL
Intervention: Albumex 5
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% normal serum albumin (5% NSA)
Number of subjects: 40
Study: 1536439

Group type: COMPARATOR
Intervention: Nitroglycerin (3.0 micrograms/kg.min)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nifedipine (0.5 microgram/kg.min)
Number of subjects: 44
Study: 4038511

Group type: COMPARATOR
Intervention: High-dose intravenous metoclopramide (MCP) at a dose of 2 mg/kg IV for three doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of high-dose intravenous metoclopramide (MCP) and intravenous dexamethasone (DXM) at a dose of 20 mg IV for three doses
Number of subjects: 30
Study: 31463735

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Guide booklet
Number of subjects: 23
Study: 30380988

Group type: EXPERIMENTAL
Intervention: 1120 primer pairs generated from SSR analysis
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Validation of selected primer pairs
Number of subjects: 177
Study: 27357297

Group type: EXPERIMENTAL
Intervention: Project delivered telephone smoking cessation counselling
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Quitline support
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Project delivered telephone cessation counselling calls
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: NRT use during counselling calls
Number of subjects: 378
Study: 23973522

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily for 4 weeks, with possible increase to 8 mg based on investigator discussion.
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily (with option to decrease to 4 mg).
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 562
Study: 22180155

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (PVI) drops
Number of subjects: 242

Group type: COMPARATOR
Intervention: 1% PVI irrigation (control)
Number of subjects: 242
Study: 20099954

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 170

Group type: COMPARATOR
Intervention: 12-step (TS)
Number of subjects: 170
Study: 18588561

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate combination
Number of subjects: 3421

Group type: COMPARATOR
Intervention: fluticasone propionate
Number of subjects: 3421
Study: 15966221

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy group (n=7) with novel arterial infusion regimen using cisplatin (CDDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=8) with no adjuvant chemotherapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy group (n=7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 15
Study: 11840104

Group type: EXPERIMENTAL
Intervention: Acute sciatica patients (Group IA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Sciatica patients at 4-year follow-up (Group IB)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patients undergoing discectomy (Group II)
Number of subjects: 128
Study: 10429744

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study: 7773582

Group type: EXPERIMENTAL
Intervention: High-dose oral/intravenous fluconazole (400 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral nystatin plus miconazole inhalations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Empiric amphotericin B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Systematic fungal infection
Number of subjects: 90
Study: 2275309

Group type: EXPERIMENTAL
Intervention: Topical zinc oxide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Zinc sulfate at three different concentrations
Number of subjects: 37

Group type: COMPARATOR
Intervention: Zinc deficiency
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zinc oxide medicated occlusive dressing
Number of subjects: 37
Study: 7404497

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous (IV) heparin
Number of subjects: 100
Study: 31521029

Group type: EXPERIMENTAL
Intervention: Parent training program (7 sessions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 28820753

Group type: EXPERIMENTAL
Intervention: Ocular lubricants
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bandage contact lenses
Number of subjects: 104

Group type: COMPARATOR
Intervention: Punctal plugs
Number of subjects: 104
Study: 24298982

Group type: EXPERIMENTAL
Intervention: Cylindrical implant
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Conical/cylindrical implant
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 23477479

Group type: EXPERIMENTAL
Intervention: Integrated parenting intervention for ADHD (IPI-A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard behavioral parent training (BPT)
Number of subjects: 98
Study: 21368077

Group type: EXPERIMENTAL
Intervention: Single-event multilevel surgery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (progressive resistance strength training)
Number of subjects: 19